CA2290818A1 - Pharmaceutical agents for the treatment of cerebral amyloidosis - Google Patents

Pharmaceutical agents for the treatment of cerebral amyloidosis Download PDF

Info

Publication number
CA2290818A1
CA2290818A1 CA002290818A CA2290818A CA2290818A1 CA 2290818 A1 CA2290818 A1 CA 2290818A1 CA 002290818 A CA002290818 A CA 002290818A CA 2290818 A CA2290818 A CA 2290818A CA 2290818 A1 CA2290818 A1 CA 2290818A1
Authority
CA
Canada
Prior art keywords
alkyl
group
dms
compound
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002290818A
Other languages
English (en)
French (fr)
Inventor
Paul Averback
Hossein Ghanbari
Iraj Beheshti
David Morse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nymox Corp Canada
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2290818A1 publication Critical patent/CA2290818A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/28—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by unsaturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
    • C07C217/10—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/164—Unsaturated ethers containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/17—Unsaturated ethers containing halogen
    • C07C43/174—Unsaturated ethers containing halogen containing six-membered aromatic rings
    • C07C43/1745—Unsaturated ethers containing halogen containing six-membered aromatic rings having more than one ether bound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002290818A 1997-05-19 1998-05-19 Pharmaceutical agents for the treatment of cerebral amyloidosis Abandoned CA2290818A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/858,343 1997-05-19
US08/858,343 US6130221A (en) 1997-03-05 1997-05-19 Pharmaceutical agents that impede the initiation and progression of primary and secondary DMS disruptions
PCT/US1998/010218 WO1998052898A1 (en) 1997-05-19 1998-05-19 Pharmaceutical agents for the treatment of cerebral amyloidosis

Publications (1)

Publication Number Publication Date
CA2290818A1 true CA2290818A1 (en) 1998-11-26

Family

ID=25328087

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002290818A Abandoned CA2290818A1 (en) 1997-05-19 1998-05-19 Pharmaceutical agents for the treatment of cerebral amyloidosis

Country Status (7)

Country Link
US (2) US6130221A (enExample)
EP (2) EP1930308A1 (enExample)
JP (1) JP2002502375A (enExample)
AU (1) AU743845B2 (enExample)
CA (1) CA2290818A1 (enExample)
DE (1) DE69838785D1 (enExample)
WO (1) WO1998052898A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525339A (en) * 1986-08-27 1996-06-11 Dms Pharmaceutical Inc. Isolated components of dense microspheres derived from mammalian brain tissue and antibodies thereto
GB9911802D0 (en) * 1999-05-20 1999-07-21 Merck Sharp & Dohme Therapeutic combination
EP1829535A3 (en) * 1999-10-27 2007-10-24 Tanox, Inc. Tissue factor antagonists and methods of use thereof
AU784426C (en) 1999-10-27 2007-02-01 Tanox, Inc. Tissue factor antagonists and methods of use thereof
CA2404858A1 (en) * 2000-04-12 2001-10-25 Minerva Biotechnologies Corporation Treatment of neurodegenerative disease
US20020160988A1 (en) * 2001-02-20 2002-10-31 Israel Institute For Biological Research Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof
US7544681B2 (en) 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
US7514407B2 (en) * 2002-03-04 2009-04-07 Nymox Corporation Spheron component peptides and pharmaceutical compositions
EP1481007B1 (en) * 2002-03-04 2007-01-24 Nymox Corporation Spheron components useful in determining compounds capable of treating symptoms of alzheimer's disease, treatments and animal models produced therefrom
CN101511388B (zh) 2006-07-17 2012-10-24 特拉维夫大学拉莫特有限公司 含有精神药物或gaba激动剂和有机酸的缀合物以及它们在治疗疼痛和其它cns疾病中的用途
WO2011070579A1 (en) 2009-12-09 2011-06-16 Biolinerx Ltd. Methods of improving cognitive functions
CN102858345A (zh) 2010-02-24 2013-01-02 雷蒙特亚特特拉维夫大学有限公司 奋乃静-gaba的三甲磺酸盐的晶型及其制备方法
WO2012038963A1 (en) * 2010-09-22 2012-03-29 Ramot At Tel-Aviv University Ltd. An acid addition salt of a nortriptyline-gaba conjugate and a process of preparing same
CN103896729A (zh) * 2012-12-28 2014-07-02 北大方正集团有限公司 一种制备4-氯双苯氯甲烷的方法
MX2022002282A (es) 2019-08-28 2022-03-25 Unilever Ip Holdings B V Compuestos novedosos para aclarar la piel.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL221816A (enExample) * 1957-10-22
US3060242A (en) * 1958-10-01 1962-10-23 Dow Chemical Co Aralkyl ether
US4540564A (en) * 1982-05-18 1985-09-10 University Of Florida Brain-specific drug delivery
ES8308553A1 (es) * 1982-06-17 1983-09-01 Ferrer Int "procedimiento de obtencion de nuevos derivados de piperazina".
BG41728A1 (en) * 1984-12-28 1987-08-14 Ninov Crystal form of 1- benzhydryl- 4- adyl- piperazine dihydrochloride and method for its preparation
US4816416A (en) * 1986-08-27 1989-03-28 Paul Averback Microspheric bodies for use in screening therapies for Azheimer's disease and related conditions
US5231170A (en) * 1986-08-27 1993-07-27 Paul Averback Antibodies to dense microspheres
US4919915A (en) * 1987-03-03 1990-04-24 Paul Averback Method for detecting the ability to prevent red-to-green congophilic birefringence
US5280032A (en) * 1989-02-14 1994-01-18 Toyama Chemical Co., Ltd. 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same

Also Published As

Publication number Publication date
AU743845B2 (en) 2002-02-07
DE69838785D1 (de) 2008-01-10
EP0983222A1 (en) 2000-03-08
JP2002502375A (ja) 2002-01-22
AU7579398A (en) 1998-12-11
US6130221A (en) 2000-10-10
WO1998052898A9 (en) 1999-04-01
EP0983222B1 (en) 2007-11-28
EP1930308A1 (en) 2008-06-11
WO1998052898A1 (en) 1998-11-26
US6518314B1 (en) 2003-02-11

Similar Documents

Publication Publication Date Title
AU743845B2 (en) Pharmaceutical agents for the treatment of cerebral amyloidosis
DK2349238T3 (en) CO-CRYSTALS of tramadol and NSAIDs
RU2118320C1 (ru) Энантиомеры 1-[(4-хлорфенил)фенилметил]-4-[(4-метилфенил)сульфонил]пиперазина, способ их получения, способ получения энантиомеров 1-[(4-хлорфенил)фенилметил]пиперазина, энантиомеры 1-[(4-хлорфенил)фенилметил]пиперазина,энантиомеры производных 1-[(4-хлорфенил)фенилметил]пиперазина
BG106291A (bg) Метод за инхибиране на натрупване от амилоиден протеин и за изобразяване на амилоидни отлагания, използвайки производни на изоиндолин
JPH07223953A (ja) 中枢神経系疾患治療用薬剤組成物
JP2022000421A (ja) τリン酸化を阻害する方法
JP2000500786A (ja) エーテルムスカリン様アンタゴニスト
US5310756A (en) Aryloxyphenylpropylamines and their calcium overload blocking compositions and methods of use
US7691849B2 (en) Carboxamidine derivatives and their use in the treatment of vascular diseases
AU610297B2 (en) Aryloxyphenylpropylamines and their preparation and use
JP7612850B2 (ja) ピリジニルフェニル化合物の結晶及びその製造方法
EP2022778A1 (en) A crystalline form of (R,R)-tramadol-(S)-naproxene salt
JPH04178356A (ja) 光学活性なベンジルアルコール誘導体及びその用途
IE46171B1 (en) N-(1'-allyl-2'-pyrrolidylmethyl)-2,3-dimethoxy-5-sulphamoylbenzamide and derivatives
WO2024015730A2 (en) Amphiphilic compounds for attenuating neurotoxicity of amyloid-beta oligomers and diagnostic methods
JP2003502320A (ja) アミロイドタンパク質凝集を阻害し、アミロイド沈着物を画像化する方法に使用するためのローダニン誘導体
EP1978959B1 (en) Piperidine and piperazine derivatives
CN116199622A (zh) α-突触核蛋白聚集体的小分子结合配体及其用途
SK8532002A3 (en) Substituted 1 and 2 naphthol Mannich bases
CN116554144B (zh) 一种sj系列芳基苯胺类化合物及其制备方法与医药用途
CN108727350A (zh) 一类哌啶烷基苯酞类化合物、其制备方法和用途
HK1160035B (en) Co-crystals of tramadol and nsaids
KR20000049778A (ko) 다중히드록시스틸벤 계열의 류코트리엔ｄ4 길항제항천식물질

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued